My Account
Log in Registration
All
Cart
Highlights
Fiction Books
Non-Fiction Books
Children's Books
Rare Books
Music
DVD & Blu-Ray
Video Games
Category
Wishlists
Cart
All
Free US shipping over $10
Trustpilot
Proud to be B-Corp

Antibody-Drug Conjugates and Immunotoxins Gail Lewis Phillips

Antibody-Drug Conjugates and Immunotoxins By Gail Lewis Phillips

Antibody-Drug Conjugates and Immunotoxins by Gail Lewis Phillips

Reviews:
$201.29
Condition - New
Only 2 left
New

Summary

This volume gathers the leading research on antibody-drug conjugates and immunotoxins. Following a rigorous overview, the volume delves into focused sections on all aspects of ADCs and ITs from clinical development through to targeted therapeutic applications and the latest technologies.

Antibody-Drug Conjugates and Immunotoxins Summary

Antibody-Drug Conjugates and Immunotoxins: From Pre-Clinical Development to Therapeutic Applications by Gail Lewis Phillips

This volume gathers the leading research on antibody-drug conjugates and immunotoxins. Following a rigorous overview, the volume delves into focused sections on all aspects of ADCs and ITs from clinical development through to targeted therapeutic applications and the latest technologies.

Table of Contents

Antibody Directed Delivery for Treatment of Cancer: Antibody Drug Conjugates and Immunotoxins.- Antibody-Drug Conjugate Development.- Components of ADC Development: Assay Methodologies and Challenges.- Clinical Pharmacology Strategies in the Development of Antibody-Drug Conjugates.- Predictive Biomarkers for Antibody-Drug Conjugates.- Factors Involved in the Design of Cytotoxic Payloads for Antibody-Drug Conjugates.- Linker Technology and Impact of Linker Design on ADC Properties.- Antibody-drug conjugates for the treatment of B-cell malignancies.- Targeting CD19 with SAR3419, an anti-CD19-Maytansinoid Conjugate for the Treatment of B Cell Malignancies.- Brentuximab Vedotin (SGN-35) for CD30 Positive Malignancies.- Trastuzumab Emtansine (T-DM1) for the Treatment of HER2-Positive Cancer.- CDX-011 (Glembatumumab Vedotin, CR011-vcMMAE).- Case Study: An Antibody-Drug Conjugate Targeting MUC16 for Ovarian Cancer.- EphA2 Immunoconjugate.- Anti-PSMA Antibody-Drug Conjugates.- Targeting CD56 (NCAM)-expressing Neoplasms with Lorvotuzumab Mertansine.- Studies on the Metabolism of Antibody-Drug Conjugates.- Design, Development and Characterization of Recombinant Immunotoxins Targeting HER2/neu.- The Preclinical and Clinical Evaluation of VB6-845: An Immunotoxin with a De-Immunized Payload for the Systemic Treatment of Solid Tumors.- Index.

Additional information

NLS9781489997005
9781489997005
1489997008
Antibody-Drug Conjugates and Immunotoxins: From Pre-Clinical Development to Therapeutic Applications by Gail Lewis Phillips
Gail Lewis Phillips
Cancer Drug Discovery and Development
New
Paperback
Springer-Verlag New York Inc.
2015-01-28
378
N/A
Book picture is for illustrative purposes only, actual binding, cover or edition may vary.
This is a new book - be the first to read this copy. With untouched pages and a perfect binding, your brand new copy is ready to be opened for the first time

Customer Reviews - Antibody-Drug Conjugates and Immunotoxins